Impact of Preimmunization on Adenoviral Vector Expression and Toxicity in a Subcutaneous Mouse Cancer Model

This publication has 19 references indexed in Scilit:

• A Pilot Study ofIn VivoLiver-Directed Gene Transfer with an Adenoviral Vector in Partial Ornithine Transcarbamylase Deficiency
  Human Gene Therapy, 2002
• Lethal Toxicity, Severe Endothelial Injury, and a Threshold Effect with High Doses of an Adenoviral Vector in Baboons
  Human Gene Therapy, 2002
• Complement activation by recombinant adenoviruses
  Gene Therapy, 2001
• Enhanced therapeutic effect of mutiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model
  International Journal of Radiation Oncology*Biology*Physics, 2001
• Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer—A preliminary report
  International Journal of Radiation Oncology*Biology*Physics, 2001
• Prostate-Specific Antigen Response and Systemic T Cell Activation After In Situ Gene Therapy in Prostate Cancer Patients Failing Radiotherapy
  Human Gene Therapy, 2001
• In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical Trial
  Human Gene Therapy, 1999
• Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
  Gene Therapy, 1997
• Immune Responses to Reporter Proteins and High Viral Dose Limit Duration of Expression with Adenoviral Vectors: Comparison of E2a Wild Type and E2a Deleted Vectors
  Human Gene Therapy, 1997
• Adenoviral vectors for gene transfer
  Advanced Drug Delivery Reviews, 1993